JP7675094B2 - トリアゾロン化合物 - Google Patents

トリアゾロン化合物 Download PDF

Info

Publication number
JP7675094B2
JP7675094B2 JP2022558347A JP2022558347A JP7675094B2 JP 7675094 B2 JP7675094 B2 JP 7675094B2 JP 2022558347 A JP2022558347 A JP 2022558347A JP 2022558347 A JP2022558347 A JP 2022558347A JP 7675094 B2 JP7675094 B2 JP 7675094B2
Authority
JP
Japan
Prior art keywords
methyl
amino
pyrimidin
triazolo
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022558347A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519362A (ja
JP2023519362A5 (https=
Inventor
アルバート ブラウン，ジレス
メアリー リチャードソン，クリスティン
スチュアート コングリーブ，マイルズ
ポール，レベッカ
フィリップ アンドリューズ，スティーブン
スティーブン メイソン，ジョナサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Nxera Pharma UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nxera Pharma UK Ltd filed Critical Nxera Pharma UK Ltd
Publication of JP2023519362A publication Critical patent/JP2023519362A/ja
Publication of JP2023519362A5 publication Critical patent/JP2023519362A5/ja
Application granted granted Critical
Publication of JP7675094B2 publication Critical patent/JP7675094B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022558347A 2020-03-26 2021-03-25 トリアゾロン化合物 Active JP7675094B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062994908P 2020-03-26 2020-03-26
US62/994,908 2020-03-26
PCT/EP2021/057806 WO2021191378A1 (en) 2020-03-26 2021-03-25 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer

Publications (3)

Publication Number Publication Date
JP2023519362A JP2023519362A (ja) 2023-05-10
JP2023519362A5 JP2023519362A5 (https=) 2024-04-01
JP7675094B2 true JP7675094B2 (ja) 2025-05-12

Family

ID=75339740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022558347A Active JP7675094B2 (ja) 2020-03-26 2021-03-25 トリアゾロン化合物

Country Status (8)

Country Link
US (1) US20230271964A1 (https=)
EP (1) EP4126872A1 (https=)
JP (1) JP7675094B2 (https=)
KR (1) KR20230049579A (https=)
CN (1) CN115867282B (https=)
AU (1) AU2021240344A1 (https=)
CA (1) CA3176944A1 (https=)
WO (1) WO2021191378A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3243621A1 (en) * 2022-02-01 2023-08-10 Eli Lilly And Company METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138734A1 (en) 2005-06-17 2006-12-28 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457988T1 (de) 2006-06-26 2010-03-15 Schering Corp A2a-adenosin-rezeptor-antagonisten
AU2011306358B2 (en) 2010-09-24 2014-08-14 Impetis Biosciences Ltd. Fused tricyclic compounds as adenosine receptor antagonist
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
AU2018233367B2 (en) 2017-03-16 2021-08-12 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138734A1 (en) 2005-06-17 2006-12-28 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物

Also Published As

Publication number Publication date
EP4126872A1 (en) 2023-02-08
US20230271964A1 (en) 2023-08-31
CN115867282B (zh) 2025-05-27
KR20230049579A (ko) 2023-04-13
CN115867282A (zh) 2023-03-28
WO2021191378A1 (en) 2021-09-30
JP2023519362A (ja) 2023-05-10
CA3176944A1 (en) 2021-09-30
AU2021240344A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
TWI912127B (zh) KRas G12D抑制劑
CN111936499B (zh) Mat2a的杂二环抑制剂和用于治疗癌症的方法
CN112513029B (zh) 含氮芳基磷氧化物类衍生物、其制备方法和应用
JP6159028B2 (ja) Ｓｙｋ阻害剤
KR101862493B1 (ko) Fgfr4 억제제로서의 고리-융합된 비시클릭 피리딜 유도체
TW202430532A (zh) 大環ｋｒａｓ抑制劑及使用方法
EP4305038A1 (en) Kras g12d inhibitors
JP7406674B2 (ja) スピロ環化合物
KR20250048078A (ko) Kras 억제제
CN117957226A (zh) 作为sos1抑制剂的杂环化合物及其用途
JP7675094B2 (ja) トリアゾロン化合物
TW202204362A (zh) 作為PI3K-γ抑制劑之雜環化合物
EP2435438A1 (en) Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
KR20160013188A (ko) 헤지호그 신호전달 경로 억제제로서의 헤테로사이클릭 화합물
AU2020410470A1 (en) Triazolopyridazine derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof
BR112021010273A2 (pt) derivados de amino triazolo quinazolina substituídos em 7, 8 e 10 como antagonistas do receptor de adenosina, composições farmacêuticas e seu uso
JP2024502097A (ja) 三環式化合物とその用途
JP7709454B2 (ja) トリアゾロン化合物
CN115867280B (zh) 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
TW202529739A (zh) Parg之抑制劑

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250425

R150 Certificate of patent or registration of utility model

Ref document number: 7675094

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150